Radiopharm Theranostics Limited (AU:RAD) has released an update.
Radiopharm Theranostics Limited, a clinical-stage company specializing in radiopharmaceutical products for cancer diagnosis and therapy, has successfully presented their joint venture, Radiopharm Ventures, at a significant US biotech event. The presentation highlighted their lead therapeutic agent, RV 01, which targets cancer cells without affecting healthy tissue, and introduced a new platform technology. This exposure garnered strong interest from attending US biotech specialized funds and venture capital firms.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.
